Allogeneic transplantation following non-myeloablative conditioning in renal carcinoma. New evidence of the immune mechanisms responsible for the activity of this form of immunotherapy and the pathogenetic role of endogenous retroviruses

Oncology Reviews

Volumn 2, Issue 1, 2008, Pages 1-3

  Porta, Camillo ^a  

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873599808     PISSN: 19705557     EISSN: 19705565     Source Type: Journal    
DOI: 10.1007/s12156-008-0049-1     Document Type: Review

References (26)

1. Childs R, Chernoff A, Contentin N et al (2000) Regression of metastatic renal-cell carcinoma after non myeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med 343:750-758
2. Rosenberg SA, Yang JC, Topalian SL et al (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:907-913
3. Bregni M, Dodero A, Peccatori J et al (2002) Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 99:4234-4236 (Pubitemid 35332074)
4. Pedrazzoli P, Da Prada GA, Giorgiani G et al (2002) Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies. Cancer 94:2409-2415 (Pubitemid 34457122)
5. Rini BI, Zimmerman T, Stadler WM et al (2002) Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results. J Clin Oncol 20:2017-2024 (Pubitemid 34408790)
6. Ueno NT, Cheng YC, Rondón G et al (2003) Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102:3829-3836 (Pubitemid 37409408)
7. Hentschke P, Barkholt L, Uzunel M et al (2003) Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 31:253-261 (Pubitemid 36336227)
8. Baron F, Frère P, Baudoux E et al (2003) Non-myeloablative stem cell transplantation with low-dose total body irradiation and fludarabine for metastatic renal cell carcinoma. Haematologica 88:478-480 (Pubitemid 36547139)
9. Blaise D, Bay JO, Faucher C et al (2004) Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood 103:435-441 (Pubitemid 38140070)
10. Nakagawa T, Kami M, Hori A et al (2004) Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up. Exp Hematol 32:599-606 (Pubitemid 38891528)
11. Massenkeil G, Roigas J, Nagy M et al (2004) Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity. Bone Marrow Transplant 34:309-316 (Pubitemid 39172437)
12. Tykodi SS, Warren EH, Thompson JA et al (2004) Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens. Clin Cancer Res 10:7799-7811 (Pubitemid 39587517)
13. Rini BI, Halabi S, Barrier R et al (2006) Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study. Biol Blood Marrow Transplant 12:778-785 (Pubitemid 43899414)
14. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125-134 (Pubitemid 46089673)
15. Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115-124 (Pubitemid 46089672)
16. Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281 (Pubitemid 46849157)
17. Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103-2111 (Pubitemid 350296300)
18. Sprangers B, Van Wijmeersch B, Fevery S et al (2007) Experimental and clinical approaches for optimization of the graftversus-leukemia effect. Nat Clin Pract Oncol 4:404-414 (Pubitemid 47039691)
19. Takahashi Y, Harashima N, Kajigaya S et al (2008) Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. J Clin Invest 118:1099-1109 (Pubitemid 351364617)
20. Löwer R, Löwer J, Kurth R et al (1996) The viruses in all of us: characteristics and biological significance of human endogenous retrovirus sequences. Proc Natl Acad Sci USA 93:5177-5184 (Pubitemid 26159422)
21. Griffiths DJ (2001) Endogenous retroviruses in the human genome sequence. Genome Biol 2:2017
22. Seifarth W, Frank O, Zeilfelder U et al (2005) Comprehensive analysis of human endogenous retrovirus transcriptional activity in human tissues with a retrovirus-specific microarray. J Virol 79:341-352 (Pubitemid 39648388)
23. Büscher K, Trefzer U, Hofmann M et al (2005) Expression of human endogenous retrovirus K in melanomas and melanoma cell lines. Cancer Res 65:4172-4180 (Pubitemid 40775655)
24. Depil S, Roche C, Dussart P, Prin L (2002) Expression of a human endogenous retrovirus, HERV-K, in the blood cells of leukemia patients. Leukemia 16:254-259 (Pubitemid 34145143)
25. Muster T, Waltenberger A, Grassauer A et al (2003) An endogenous retrovirus derived from human melanoma cells. Cancer Res 63:8735-8741 (Pubitemid 38064051)
26. Schiavetti F, Thonnard J, Colau D et al (2002) A human endogenous retroviral sequence encoding an antigen recognized on melanoma by cytolytic T lymphocytes. Cancer Res 62:5510-5516